- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05884398
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC (LIBERTAS)
March 25, 2024 updated by: Janssen Research & Development, LLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level < 0.2 nanograms/millilitres (ng/mL) after 6 months of treatment with apalutamide and ADT combination therapy provides non-inferior radiographic progression-free survival (rPFS) and a reduced burden of hot flashes measured as 18-month percent change in severity adjusted hot flash score.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
333
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Study Contact
- Phone Number: 844-434-4210
- Email: Participate-In-This-Study@its.jnj.com
Study Locations
-
-
-
Macquarie University, Australia, 2109
- Recruiting
- Macquarie University Hospital
-
Melbourne, Australia, 3000
- Recruiting
- Peter MacCallum Cancer Centre
-
South Brisbane, Australia, 4101
- Recruiting
- Mater Misericordiae Hospital
-
-
-
-
-
Barretos, Brazil, 14784-400
- Recruiting
- Fundação PIO XII
-
Natal, Brazil, 59062-000
- Recruiting
- Liga Norte Riograndense Contra O Câncer
-
Salvador, Brazil, 41253 190
- Recruiting
- Instituto D Or de Pesquisa e Ensino
-
Santo André, Brazil, 09060-650
- Recruiting
- CEPHO - Centro de Estudos e Pesquisa de Hematologia e Oncologia
-
-
-
-
-
Quebec, Canada, G1J 1Z4
- Recruiting
- CHU de Quebec Universite Laval Hopital de l Enfant Jesus
-
-
Alberta
-
Calgary, Alberta, Canada, T2V 1P9
- Recruiting
- Southern Alberta Institute of Urology / Prostate Cancer Centre
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Recruiting
- Nova Scotia Health Authority
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Recruiting
- Sunnybrook Health Sciences Center
-
Toronto, Ontario, Canada, M5G 2M9
- Recruiting
- Princess Margaret Hospital
-
-
-
-
-
Beijing, China, 100034
- Recruiting
- Peking University First Hospital
-
Changchun, China, 130021
- Recruiting
- The First Hospital of Jilin University
-
Chengdu, China, 610041
- Recruiting
- West China School of Medicine/West China Hospital, Sichuan University
-
Guangzhou, China, 510080
- Recruiting
- The First Affiliated Hospital, Sun Yat-sen University
-
Guangzhou, China, 510515
- Recruiting
- Nanfang Hospital of Southern Medical Hospital
-
Jinan, China, 250021
- Recruiting
- Shandong Provincial Hospital
-
Ningbo, China, 315010
- Recruiting
- Ningbo First Hospital
-
Shenyang, China, 110004
- Recruiting
- ShengJing Hospital Of China Medical University
-
Wuhan, China, 430030
- Recruiting
- TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
-
XI An, China, 710061
- Recruiting
- The First Affiliated Hospital of Xian Jiaotong University
-
-
-
-
-
Lyon, France, 69373
- Recruiting
- Centre Léon Bérard
-
Paris, France, 75014
- Recruiting
- Hôpital COCHIN
-
Rennes, France, 35000
- Recruiting
- Chu Rennes Hopital Pontchaillou
-
Villejuif Cedex, France, 94805
- Recruiting
- Gustave Roussy
-
-
-
-
-
Aachen, Germany, 52074
- Recruiting
- Universitaetsklinikum der RWTH Aachen
-
Augsburg, Germany, D-86158
- Recruiting
- Klinikum Augsburg
-
Dresden, Germany, 01307
- Recruiting
- Universitaetsklinikum Carl Gustav Carus TU Dresden
-
Koeln, Germany, 50937
- Recruiting
- Universitaetsklinikum Koelnt
-
Muenchen, Germany, 81675
- Recruiting
- Klinikum rechts der Isar - der Technischen Universität München
-
Nuertingen, Germany, 72622
- Recruiting
- Studienpraxis Urologie Nurtingen
-
Würzburg, Germany, 97080
- Recruiting
- Universitätsklinikum Würzburg
-
-
-
-
-
Chihuahua, Mexico, 31207
- Recruiting
- Scientia Investigacion Clinica SC
-
Queretaro, Mexico, 76000
- Recruiting
- Cuidados oncologicos
-
-
-
-
-
Bydgoszcz, Poland, 85-796
- Recruiting
- Centrum Onkologii im. Prof. F. Lukaszczyka
-
Koszalin, Poland, 75-581
- Recruiting
- Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie
-
Warszawa, Poland, 04-073
- Recruiting
- Szpital Grochowski im. dr med. Rafała Masztaka Sp. z o.o.
-
Warszawa, Poland, 02 781
- Recruiting
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
Wroclaw, Poland, 53-329
- Recruiting
- Specjalistyczna przychodnia lekarska POLIMED
-
-
-
-
Alabama
-
Homewood, Alabama, United States, 35209
- Recruiting
- Urology Centers of Alabama
-
-
Arizona
-
Tucson, Arizona, United States, 85741
- Recruiting
- Arizona Urology Specialists
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72211
- Recruiting
- Arkansas Urology
-
-
California
-
Santa Barbara, California, United States, 93105
- Recruiting
- Sansum Clinic Pharm
-
-
Colorado
-
Lakewood, Colorado, United States, 80228
- Recruiting
- Colorado Clinical Research
-
-
Florida
-
Daytona Beach, Florida, United States, 32114
- Recruiting
- Advanced Urology Institute
-
-
Illinois
-
Chicago Ridge, Illinois, United States, 60415
- Recruiting
- Associated Urological Specialists LLC
-
Joliet, Illinois, United States, 60431
- Recruiting
- Advanced Urology Associates
-
-
Indiana
-
Greenwood, Indiana, United States, 46143
- Recruiting
- Urology of Indiana
-
Jeffersonville, Indiana, United States, 47130
- Recruiting
- First Urology, PSC
-
-
Maryland
-
Silver Spring, Maryland, United States, 20904
- Recruiting
- Maryland Oncology Hematology P A
-
Towson, Maryland, United States, 21204
- Recruiting
- Chesapeake Urology Research Associates
-
-
Michigan
-
Troy, Michigan, United States, 48084
- Recruiting
- Michigan Institute of Urology
-
-
New Jersey
-
Basking Ridge, New Jersey, United States, 07920
- Recruiting
- MSKCC Basking Ridge
-
Middletown, New Jersey, United States, 07748
- Recruiting
- MSKCC Monmouth
-
Montvale, New Jersey, United States, 07645
- Recruiting
- MSKCC Bergen
-
-
New York
-
Commack, New York, United States, 11725
- Recruiting
- MSKCC Commack
-
Harrison, New York, United States, 10604
- Recruiting
- MSKCC Westchester
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
New York, New York, United States, 10032
- Recruiting
- Columbia University Medical Center
-
Syracuse, New York, United States, 13210
- Recruiting
- Associated Medical Professionals
-
Uniondale, New York, United States, 11553
- Recruiting
- MSKCC Nassau Regional Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45212
- Recruiting
- TriState Urologic Services PSC Inc. DBA The Urology Group
-
Gahanna, Ohio, United States, 43230
- Recruiting
- Central Ohio Urology Group
-
Middleburg Heights, Ohio, United States, 44130
- Recruiting
- Helios Clinical Research, LLC
-
-
Oregon
-
Tigard, Oregon, United States, 97223
- Recruiting
- Northwest Cancer Specialists PC
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, United States, 19004
- Recruiting
- Centers for Advanced Urology LLC d b a MidLantic Urology
-
Pittsburgh, Pennsylvania, United States, 15240
- Recruiting
- VA Pittsburgh
-
-
Tennessee
-
Nashville, Tennessee, United States, 37209
- Recruiting
- Urology Associates
-
-
Texas
-
Austin, Texas, United States, 78731
- Recruiting
- Texas Oncology P A
-
Dallas, Texas, United States, 75390
- Recruiting
- UT Southwestern Medical Center
-
Dallas, Texas, United States, 75246
- Recruiting
- Texas Oncology P.A.
-
Houston, Texas, United States, 77027
- Recruiting
- Houston Metro Urology
-
Houston, Texas, United States, 77024
- Recruiting
- Texas Oncology P.A.
-
San Antonio, Texas, United States, 78217
- Recruiting
- Texas Oncology San Antonio Northeast
-
Wichita Falls, Texas, United States, 76310
- Recruiting
- Texas Oncology P.A.
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
- Recruiting
- Virginia Oncology Associates
-
Roanoke, Virginia, United States, 98684
- Recruiting
- Oncology and Hematology Associates of Southwest Virginia, Inc.
-
Virginia Beach, Virginia, United States, 23462
- Recruiting
- Urology of Virginia, PLLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosis of prostate cancer prior to screening with histologically or cytologically confirmed adenocarcinoma of the prostate
- Metastatic prostate cancer disease documented by conventional imaging (example, computed tomography [CT], magnetic resonance imaging [MRI], or bone scan) and/or next-generation imaging [NGI] demonstrating greater than equal (>=) 2 distinct extraprostatic sites of metastasis
- Have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1. Participants with ECOG PS 2 or 3 are eligible for the study if the ECOG PS score is related to stable physical limitations (example, wheelchair-bound due to prior spinal cord injury) and not related to prostate cancer or associated therapy
- A participant must agree not to plan to conceive a child while enrolled in this study or within 3 months after the last dose of study treatment
- Must be able to take whole apalutamide tablets by swallowing alone or with another vehicle (example, applesauce)
- Assigned male at birth, inclusive of all gender identities
- Participants who have undergone a bilateral orchidectomy and/or who are actively taking gender-affirming hormone therapy as part of their gender affirming care
Exclusion Criteria:
- History of seizure or known condition that has been determined to significantly predispose to seizure per investigator
- Pelvic lymph nodes as only site of metastasis
- Known allergies, hypersensitivity, or intolerance to excipients of apalutamide
- Any of the following within 6 months prior to screening: severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, uncontrolled hypertension, clinically significant arterial or venous thromboembolic events
- Gastrointestinal disorder affecting absorption
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A (Intermittent ADT Group)
Participants with PSA level <0.2 ng/mL after 6 months of treatment with Apalutamide and ADT during initial treatment phase, will enter main treatment phase and treated with apalutamide with intermittent ADT per protocol or followed up for at least 18 months from Day 1 of Cycle 7 (each cycle 28 days) or have discontinued the study, whichever occurs first.
|
Apalutamide will be administered orally from Day 1 of Cycle 1 till 6 months in initial treatment phase and then in main treatment phase from Day 1 of Cycle 7 up to at least 18 months.
The choice of ADT will be at discretion of the Investigator.
Dosing (dose and frequency of administration) will be consistent with the prescribing information.
|
Experimental: Arm B (Continuous ADT Group)
Participants with PSA level <0.2 ng/mL after 6 months of treatment with Apalutamide and ADT during initial treatment phase, will enter main treatment phase and continue to receive apalutamide plus ADT or followed up for at least 18 months from Day 1 of Cycle 7 (each cycle 28 days) or have discontinued the study, whichever occurs first.
|
Apalutamide will be administered orally from Day 1 of Cycle 1 till 6 months in initial treatment phase and then in main treatment phase from Day 1 of Cycle 7 up to at least 18 months.
The choice of ADT will be at discretion of the Investigator.
Dosing (dose and frequency of administration) will be consistent with the prescribing information.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With 18-Months Radiographic Progression-free Survival (rPFS)
Time Frame: From randomization (Day 1 of Cycle 7) up to 18 months
|
rPFS is defined as the duration from the date of randomization to the date of first documentation of confirmed radiographic progressive disease or death due to any cause, whichever occurs first.
rPFS will be assessed by investigators using conventional imaging (computed tomography [CT]/magnetic resonance imaging [MRI] and 99mTc bone scans).
|
From randomization (Day 1 of Cycle 7) up to 18 months
|
Percent Change From Randomization in Severity of Adjusted Hot Flash Score at 18 Months
Time Frame: From randomization (Day 1 of Cycle 7) up to 18 months
|
Severity adjusted hot flash score will be calculated from the hot flash diary which will be daily filled by the participants.
|
From randomization (Day 1 of Cycle 7) up to 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Percentage Changes From Randomization in Severity Adjusted Hot Flash Score and Hot Flash Frequency
Time Frame: From randomization (Day 1 of Cycle 7), up to 3 years 3 months
|
Severity adjusted hot flash score and hot flash frequency will be calculated from the hot flash diary which will be daily filled by the participants.
|
From randomization (Day 1 of Cycle 7), up to 3 years 3 months
|
Second Progression-free Survival (PFS2)
Time Frame: From randomization (Day 1 of Cycle 7) up to 3 years 3 months
|
PFS2 is defined as the duration from the date of randomization to the first occurrence of investigator-determined disease progression on the first subsequent therapy after study drug discontinuation or death, whichever occurs first.
|
From randomization (Day 1 of Cycle 7) up to 3 years 3 months
|
Overall Survival (OS)
Time Frame: From randomization (Day 1 of Cycle 7) up to 3 years 3 months
|
Overall survival time is defined as the duration from the date of randomization to the date of death from any cause.
|
From randomization (Day 1 of Cycle 7) up to 3 years 3 months
|
Prostate Cancer-specific Survival
Time Frame: From randomization (Day 1 Cycle 7) up to 3 years 3 months
|
Prostate cancer-specific survival is defined as the duration from the date of randomization to the date of death from any cause.
|
From randomization (Day 1 Cycle 7) up to 3 years 3 months
|
Serum Prostate Specific Antigen (PSA) Evaluations
Time Frame: From randomization (Day 1 of Cycle 7) up to 3 years 3 months
|
Serum PSA evaluations will be measured according to Prostate Cancer Working Group 3 (PCWG3) criteria.
|
From randomization (Day 1 of Cycle 7) up to 3 years 3 months
|
Duration of Time on Androgen-deprivation Therapy (ADT)
Time Frame: From randomization (Day 1 of Cycle 7) up to 3 years 3 months
|
Duration of time on ADT will be reported for all participants.
|
From randomization (Day 1 of Cycle 7) up to 3 years 3 months
|
Time to First ADT Restart
Time Frame: From randomization (Day 1 of Cycle 7) up to 3 years 3 months
|
Time to first ADT restart will be reported.
|
From randomization (Day 1 of Cycle 7) up to 3 years 3 months
|
Duration of Time with Testosterone Level Less than (<) 50 nanograms per millilitre (ng/mL)
Time Frame: From randomization (Day 1 of Cycle 7) up to 3 years 3 months
|
Duration of time with testosterone level <50 ng/mL will be reported.
|
From randomization (Day 1 of Cycle 7) up to 3 years 3 months
|
Time to Recovery of Testosterone >50 nanogram per decilitre (ng/dL)
Time Frame: From randomization (Day 1 of Cycle 7) up to 3 years 3 months
|
The testosterone recovery, defined as a serum testosterone >50 ng/dL will be analyzed.
|
From randomization (Day 1 of Cycle 7) up to 3 years 3 months
|
Time to Recovery of Testosterone Greater Than or Equal (>=) Screening Testosterone Level
Time Frame: From randomization (Day 1 of Cycle 7) up to 3 years 3 months
|
Time to recovery of testosterone >= screening testosterone level will be reported.
|
From randomization (Day 1 of Cycle 7) up to 3 years 3 months
|
Time to Testosterone Recovery to Normal Range (>270 ng/dL)
Time Frame: From randomization (Day 1 of Cycle 7) up to 3 years 3 months
|
Time to serum testosterone recovery to normal range (>270 ng/dL) will be reported.
|
From randomization (Day 1 of Cycle 7) up to 3 years 3 months
|
Time to Metastatic Castration-resistant Prostate Cancer (mCRPC)
Time Frame: From randomization (Day 1 of Cycle 7) up to 3 years 3 months
|
Time to mCRPC will be reported.
|
From randomization (Day 1 of Cycle 7) up to 3 years 3 months
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Initial Treatment Phase: From Day 1 of Cycle 1 (each cycle 28 days) up to end of Cycle 6 (6 month); Main Treatment Phase: Day 1 of Cycle 7 up to end of study (up to 3 years 9 months)
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event.
|
Initial Treatment Phase: From Day 1 of Cycle 1 (each cycle 28 days) up to end of Cycle 6 (6 month); Main Treatment Phase: Day 1 of Cycle 7 up to end of study (up to 3 years 9 months)
|
Number of Participants with Abnormal Clinical Laboratory Parameters
Time Frame: From Cycle 1 Day 1 up to 3 years 9 months
|
Number of participants with abnormal clinical laboratory parameters (hematology, clinical chemistry) will be reported.
|
From Cycle 1 Day 1 up to 3 years 9 months
|
Number of Participants with Abnormal Vital Sign Parameters
Time Frame: From Cycle 1 Day 1 up to 3 years 9 months
|
Number of participants with abnormal vital sign parameters (temperature, pulse/heart rate, respiratory rate, and blood pressure) will be reported.
|
From Cycle 1 Day 1 up to 3 years 9 months
|
Number of Participants with Abnormal Physical Examination Parameters
Time Frame: From Cycle 1 Day 1 up to 3 years 9 months
|
Number of Participants with Abnormal physical examination parameters will be reported.
|
From Cycle 1 Day 1 up to 3 years 9 months
|
Hot Flash Related Daily Interference Score (HFRDIS)
Time Frame: Up to 3 years 9 months
|
The HFRDIS is a 10-item scale assessing how much hot flashes interfered with various aspects of a participant's daily life.
All items are rated on a 0-10 numerical rating scale with 0 anchored as "Do Not Interfere" and 10 as "Completely Interfere."
A total score is computed by summing items.
Higher scores indicate higher interference due to hot flashes and thus, greater impact on quality of life.
|
Up to 3 years 9 months
|
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score
Time Frame: Baseline up to 3 years 9 months
|
The EORTC-QLQ-C30 (Version 3), is a self-administered, 30-item questionnaire measuring the HRQoL of participants with cancer.
The recall period for most items is the past week.
EORTC-QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status/quality of life scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).
The item and scale scores are transformed to a 0 to 100 scale.
A high scale score represents a higher response level.
Thus, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.
|
Baseline up to 3 years 9 months
|
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire -Prostate Cancer Module (EORTC-PR25) Questionnaire
Time Frame: Baseline up to 3 years 9 months
|
The EORTC-PR25 questionnaire is a supplement to the EORTC-QLQ-C30 questionnaire and is designed to assess symptoms related to prostate cancer, its treatment, and aspects of life related to this type of cancer.
|
Baseline up to 3 years 9 months
|
Change From Baseline in European Organization for the Research and Treatment of Cancer (EORTC) Customized Study Form
Time Frame: Baseline up to 3 years 9 months
|
EORTC customized study form will include 3 questions that are not included on the QLQ-30 or PR25 forms.
The items assess rash, side effect burden, and dry mouth.
|
Baseline up to 3 years 9 months
|
Change From Baseline in Patient-Reported Outcomes Measurement Information System Cognitive Function (PROMIS-Cog) Questionnaire
Time Frame: Baseline up to 3 years 9 months
|
The PROMIS-Cog is a self-administered fixed-length questionnaire of 8 items from the PROMIS item bank relating to cognitive function.
The raw domain scores are converted to standardized T-scores with a mean of 50 and a standard deviation of 10.
Higher scores indicate better cognitive functioning.
|
Baseline up to 3 years 9 months
|
Change From Baseline in Memorial Anxiety Scale for Prostate Cancer (MAX-PC) Questionnaire
Time Frame: Baseline up to 3 years 9 months
|
The MAX-PC is a patient-reported questionnaire measuring prostate cancer specific anxiety.
It consists of 18 items in 3 domains: It includes 11 items regarding prostate cancer anxiety, scored 0-33; 3 items regarding prostate-specific Antigen Anxiety, scored 0-9; and 4 items regarding fear of recurrence, scored 0-12.
Total score ranges from 0-54 with higher scores indicating greater anxiety.
|
Baseline up to 3 years 9 months
|
Change From Baseline in Patient Health Questionnaire (PHQ-9) Questionnaire
Time Frame: Baseline up to 3 years 9 months
|
The PHQ-9 is self-administered, 9-item questionnaire measuring symptoms of depression.
The recall period for all items is the past 2 weeks.
The items include diminished interest or pleasure, depressed mood, insomnia/hypersomnia, fatigue or loss of energy, weight loss or weight gain/appetite loss or appetite gain, feelings of worthlessness, diminished concentration/indecisiveness, psychomotor agitation/retardation, and thoughts of death/suicide.
Higher scores indicate more severe depressive symptoms.
|
Baseline up to 3 years 9 months
|
Change From Baseline in Patient Global Impression of Severity scale (PGIS) Questionnaire
Time Frame: Baseline up to 3 years 9 months
|
The PGIS is a self-administered, single item questionnaire measuring patients' impression of disease severity.
Participants will be asked to rate their disease severity over the past 7 days using the following 5-point scale: 1 = None, 2 = Mild, 3 = Moderate, 4 = Severe, and 5 = Very severe.
Higher scores indicate greater severity of fatigue.
|
Baseline up to 3 years 9 months
|
Change From Baseline in Patient Global Impression of Change (PGIC) Questionnaire
Time Frame: Baseline up to 3 years 9 months
|
The PGIC is self-administered, single-item questionnaire measuring patients' impression of change in disease symptoms.
Participants will be asked to rate their current symptoms as compared to when they started the study, using the following 7-point scale: 1 = Much better, 2 = Moderately better, 3 = A little better, 4 = No change, 5 = A little worse, 6 = Moderately worse, and 7 = Much worse.
A higher PGIC score indicates greater worsening of symptoms.
|
Baseline up to 3 years 9 months
|
Time to Recovery From Baseline as Assessed by EORTC-QLQ-C30
Time Frame: Baseline up to 3 years 9 months
|
Time to recovery from baseline as assessed by EORTC-QLQ-C30 will be reported.
The EORTC-QLQ-C30 (Version 3), is a self-administered, 30-item questionnaire measuring the HRQoL of participants with cancer.
The recall period for most items is the past week.
EORTC-QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status/quality of life scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).
The item and scale scores are transformed to a 0 to 100 scale.
A high scale score represents a higher response level.
Thus, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.
|
Baseline up to 3 years 9 months
|
Time to Recovery From Baseline as Assessed by EORTC-PR25
Time Frame: Baseline up to 3 years 9 months
|
Time to recovery from baseline as assessed by EORTC-PR25 will be reported.
The EORTC-PR25 questionnaire is a supplement to the EORTC-QLQ-C30 questionnaire and is designed to assess symptoms related to prostate cancer, its treatment, and aspects of life related to this type of cancer.
|
Baseline up to 3 years 9 months
|
Time to Recovery From Baseline as Assessed by EORTC Customized Study Form
Time Frame: Baseline up to 3 years 9 months
|
Time to recovery from baseline as assessed by EORTC customized study form will be reported.
EORTC customized study form will include 3 questions that are not included on the QLQ-30 or PR25 forms.
The items assess rash, side effect burden, and dry mouth.
|
Baseline up to 3 years 9 months
|
Time to Recovery From Baseline as Assessed by MAX-PC
Time Frame: Baseline up to 3 years 9 months
|
Time to recovery from baseline as assessed by MAX-PC will be reported.
The MAX-PC is a patient-reported questionnaire measuring prostate cancer specific anxiety.
It consists of 18 items in 3 domains: It includes 11 items regarding prostate cancer anxiety, scored 0-33; 3 items regarding prostate-specific Antigen Anxiety, scored 0-9; and 4 items regarding fear of recurrence, scored 0-12.
Total score ranges from 0-54 with higher scores indicating greater anxiety.
|
Baseline up to 3 years 9 months
|
Time to Recovery From Baseline as Assessed by PHQ-9
Time Frame: Baseline up to 3 years 9 months
|
Time to recovery from baseline as assessed by PHQ-9 will be reported.
The PHQ-9 is self-administered, 9-item questionnaire measuring symptoms of depression.
The recall period for all items is the past 2 weeks.
The items include diminished interest or pleasure, depressed mood, insomnia/hypersomnia, fatigue or loss of energy, weight loss or weight gain/appetite loss or appetite gain, feelings of worthlessness, diminished concentration/indecisiveness, psychomotor agitation/retardation, and thoughts of death/suicide.
Higher scores indicate more severe depressive symptoms.
|
Baseline up to 3 years 9 months
|
Time to Recovery From Baseline as Assessed by PGIS
Time Frame: Baseline up to 3 years 9 months
|
Time to recovery from baseline as assessed by PGIS will be reported.
The PGIS is a self-administered, single item questionnaire measuring patients' impression of disease severity.
Participants will be asked to rate their disease severity over the past 7 days using the following 5-point scale: 1 = None, 2 = Mild, 3 = Moderate, 4 = Severe, and 5 = Very severe.
Higher scores indicate greater severity of fatigue.
|
Baseline up to 3 years 9 months
|
Time to Recovery From Baseline as Assessed by PROMIS-Cog
Time Frame: Baseline up to 3 years 9 months
|
Time to recovery from baseline as assessed by PROMIS-Cog will be reported.
The PROMIS-Cog is a self-administered fixed-length questionnaire of 8 items from the PROMIS item bank relating to cognitive function.
The raw domain scores are converted to standardized T-scores with a mean of 50 and a standard deviation of 10.
Higher scores indicate better cognitive functioning.
|
Baseline up to 3 years 9 months
|
Time to Deterioration in EORTC-QLQ-C30 Over Time
Time Frame: Up to 3 years 9 months
|
Time to deterioration in EORTC-QLQ-C30 over time will be reported.
The EORTC-QLQ-C30 (Version 3), is a self-administered, 30-item questionnaire measuring the HRQoL of participants with cancer.
The recall period for most items is the past week.
EORTC-QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status/quality of life scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).
The item and scale scores are transformed to a 0 to 100 scale.
A high scale score represents a higher response level.
Thus, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.
|
Up to 3 years 9 months
|
Time to Deterioration in EORTC-PR25 Over Time
Time Frame: Up to 3 years 9 months
|
Time to deterioration in EORTC-PR25 over time will be reported.
The EORTC-PR25 questionnaire is a supplement to the EORTC-QLQ-C30 questionnaire and is designed to assess symptoms related to prostate cancer, its treatment, and aspects of life related to this type of cancer.
|
Up to 3 years 9 months
|
Time to Deterioration in EORTC Customized Study Form Over Time
Time Frame: Up to 3 years 9 months
|
Time to deterioration in EORTC Customized Study Form over time will be reported.
EORTC customized study form will include 3 questions that are not included on the QLQ-30 or PR25 forms.
The items assess rash, side effect burden, and dry mouth.
|
Up to 3 years 9 months
|
Time to Deterioration as per PROMIS-Cog Questionnaire Over Time
Time Frame: Up to 3 years 9 months
|
Time to deterioration as per PROMIS-Cog questionnaire over time will be reported.
The PROMIS-Cog is a self-administered fixed-length questionnaire of 8 items from the PROMIS item bank relating to cognitive function.
The raw domain scores are converted to standardized T-scores with a mean of 50 and a standard deviation of 10.
Higher scores indicate better cognitive functioning.
|
Up to 3 years 9 months
|
Time to Deterioration in MAX-PC Questionnaire Over Time
Time Frame: Up to 3 years 9 months
|
Time to deterioration in MAX-PC questionnaire over time will be reported.
The MAX-PC is a patient-reported questionnaire measuring prostate cancer specific anxiety.
It consists of 18 items in 3 domains: It includes 11 items regarding prostate cancer anxiety, scored 0-33; 3 items regarding prostate-specific Antigen Anxiety, scored 0-9; and 4 items regarding fear of recurrence, scored 0-12.
Total score ranges from 0-54 with higher scores indicating greater anxiety.
|
Up to 3 years 9 months
|
Time to Deterioration as per PHQ-9 Questionnaire Over Time
Time Frame: Up to 3 years 9 months
|
Time to deterioration as per PHQ-9 questionnaire over time will be reported.
The PHQ-9 is self-administered, 9-item questionnaire measuring symptoms of depression.
The recall period for all items is the past 2 weeks.
The items include diminished interest or pleasure, depressed mood, insomnia/hypersomnia, fatigue or loss of energy, weight loss or weight gain/appetite loss or appetite gain, feelings of worthlessness, diminished concentration/indecisiveness, psychomotor agitation/retardation, and thoughts of death/suicide.
Higher scores indicate more severe depressive symptoms.
|
Up to 3 years 9 months
|
Time to Deterioration in PGIS Questionnaire Over Time
Time Frame: Up to 3 years 9 months
|
Time to deterioration as per PGIS questionnaire over time will be reported.
The PGIS is a self-administered, single item questionnaire measuring patients' impression of disease severity.
Participants will be asked to rate their disease severity over the past 7 days using the following 5-point scale: 1 = None, 2 = Mild, 3 = Moderate, 4 = Severe, and 5 = Very severe.
Higher scores indicate greater severity of fatigue.
|
Up to 3 years 9 months
|
Time to Deterioration as per PGIC Questionnaire Over Time
Time Frame: Up to 3 years 9 months
|
Time to Deterioration as per PGIC questionnaire over time will be reported.
The PGIC is self-administered, single-item questionnaire measuring patients' impression of change in disease symptoms.
Participants will be asked to rate their current symptoms as compared to when they started the study, using the following 7-point scale: 1 = Much better, 2 = Moderately better, 3 = A little better, 4 = No change, 5 = A little worse, 6 = Moderately worse, and 7 = Much worse.
A higher PGIC score indicates greater worsening of symptoms.
|
Up to 3 years 9 months
|
Time to Recovery From Baseline as Assessed by PGIC
Time Frame: Baseline up to 3 years and 9 months
|
Time to recovery from baseline as assessed by PGIC will be reported.
The PGIC is self-administered, single-item questionnaire measuring patients' impression of change in disease symptoms.
Participants will be asked to rate their current symptoms as compared to when they started the study, using the following 7-point scale: 1 = Much better, 2 = Moderately better, 3 = A little better, 4 = No change, 5 = A little worse, 6 = Moderately worse, and 7 = Much worse.
A higher PGIC score indicates greater worsening of symptoms.
|
Baseline up to 3 years and 9 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 31, 2023
Primary Completion (Estimated)
May 31, 2027
Study Completion (Estimated)
May 31, 2027
Study Registration Dates
First Submitted
May 23, 2023
First Submitted That Met QC Criteria
May 23, 2023
First Posted (Actual)
June 1, 2023
Study Record Updates
Last Update Posted (Actual)
March 27, 2024
Last Update Submitted That Met QC Criteria
March 25, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Hypersensitivity
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Androgens
Other Study ID Numbers
- CR109327
- 56021927PCR3020 (Other Identifier: Janssen Research & Development, LLC)
- 2022-502686-24-00 (Registry Identifier: EUCT number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Castrate-sensitive Prostate Cancer
-
Suzhou Kintor Pharmaceutical Inc,CompletedMetastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Metastatic Castrate Resistant Prostate Cancer (mCRPC)United States
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingProstate Cancer | Oligometastatic Disease | Castrate Sensitive Prostate CancerUnited States
-
Herlev and Gentofte HospitalBristol-Myers SquibbRecruitingProstate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer | Prostate Cancer Stage IVDenmark
-
The University of Texas Health Science Center at...WithdrawnMetastatic Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma | Castrate Resistant Prostate CancerUnited States
-
University of Wisconsin, MadisonPfizerCompletedSolid Malignancies | Metastatic Castrate-resistant Prostate CancerUnited States
-
The First Affiliated Hospital with Nanjing Medical...RecruitingMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)China
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...European Institute of Oncology; ASST Santi Paolo e CarloRecruitingMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)Italy
-
IpsenTerminatedMetastatic Castrate Resistant Prostate CancerFrance, Spain, Poland, Belgium, Germany, Italy, Denmark, Lithuania, United Kingdom, Czechia, Hungary
-
Fudan UniversityNot yet recruitingMetastatic Prostate Cancer | Castration-Sensitive Prostate CancerChina
Clinical Trials on Apalutamide
-
Kindai UniversityJanssen Pharmaceutical K.K.RecruitingMetastatic Castration-sensitive Prostate CancerJapan
-
Aragon Pharmaceuticals, Inc.CompletedCastration-Resistant Prostate CancerUnited States, Canada, Netherlands, United Kingdom, Moldova, Republic of
-
Aragon Pharmaceuticals, Inc.Active, not recruitingProstatic NeoplasmsUnited States, Australia, France, Poland, United Kingdom, Germany, Taiwan, Spain, Belgium, Israel, Romania, Japan, Canada, Denmark, Finland, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Hungary, Austria, Sweden, Slovaki... and more
-
Janssen Research & Development, LLCWithdrawn
-
Edwin Posadas, MDEnviro Therapeutics, Inc.RecruitingCastration-resistant Prostate CancerUnited States
-
Janssen Research & Development, LLCRecruitingHepatic ImpairmentUnited States
-
Zhujiang HospitalRecruitingHigh-Risk and Oligometastatic Prostate CancerChina
-
BayerCompletedNon-metastatic Castration-resistant Prostate CancerUnited States
-
Westfälische Wilhelms-Universität MünsterJanssen Pharmaceutica N.V., BelgiumRecruitingProstatic NeoplasmsAustria, Germany
-
BayerActive, not recruitingNon-metastatic Castration-resistant Prostate CancerUnited States